Posted Sep. 4, 2009 at 2:23 p.m.

BioMarck Pharmaceuticals closes on $7.5 million in new financing

Print this blog post

Get the latest news alerts: Follow LTW at Twitter.

Local Tech Wire

RALEIGH, N.C. – Startup BioMarck Pharmaceuticals has wrapped up an effort to raise $7.5 million in new financing, according to a filing with the Securities and Exchange Commission.

The close comes five months after the drug research firm secured two more U.S. patents. It also was awarded a $990,000 National Institutes of Health grant in February.

One new patent covers its lead compound which targets mucus in respiratory diseases. The second covers anti-inflammatory research.

BioMarck’s work forces on peptides. The patents will cover treatment of pulmonary diseases related to mucus and airway inflammation, the company said. It also is seeking international patent coverage.

The lung treatment drug, which is undergoing clinical trial, is designed to combat mucus. According to BioMarck, there are no drugs that treat pulmonary disease by targeting the excessive mucus secretion.

BioMarck licensed its technology from N.C. State,

In 2007, BioMarck secured $4 million in venture funding and won U.S. patent coverage for other key parts of its technology.

Kenneth Adler, a professor of cell biology at NCSU, made the discoveries that led to the development of BioMarck’s technology.
 

Copyright 2010 Local Tech Wire. All rights reserved.
Editor’s Blog

Editor’s Blog

The latest blog posts from our Local Tech Wire and WRAL editors. Read more articles…

Featured